Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announcement: FY2026 patient-reported suspected adverse drug reactions

報告いただいた患者副作用報告に関する情報(2026年度)

Published: 2026-11-11 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-11-17

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

The Pharmaceuticals and Medical Devices Agency (PMDA) published FY2026 patient adverse-reaction report information on 2026-11-11, including drug-specific tables for April through July 2026. The page links separate tables for prescription medicines and nonprescription medicines, including medicines requiring pharmacist guidance. The supplied prescription-medicine excerpts cover April 1-July 31, 2026 and list reported drugs, reactions, counts and individual outcomes, including recovery, non-recovery, sequelae and death. The Ministry of Health, Labour and Welfare reports the reporting status to the Pharmaceutical Affairs Council's Drug Safety Subcommittee. This is a safety-information announcement; the excerpts do not establish drug-event causation or announce a regulatory change.

Business Impact

The information may be relevant to safety reviews of the listed prescription and nonprescription medicines, including medicines requiring pharmacist guidance. Patients using those medicines may encounter reports of serious outcomes, but the excerpts do not establish that the medicines caused those outcomes.

Recommended Action

A product-specific review could compare the listed drug names, reported reactions, counts and outcomes for April 1-July 31, 2026, while distinguishing patient reports from confirmed causal findings.